TY - JOUR AU - Wibmer, C. AU - Leithner, A. AU - Zielonke, N. AU - Sperl, M. AU - Windhager, R. PY - 2010 DA - 2010// TI - Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review JO - Ann Oncol VL - 21 UR - https://doi.org/10.1093/annonc/mdp415 DO - 10.1093/annonc/mdp415 ID - Wibmer2010 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2018 DA - 2018// TI - Cancer statistics, 2018 JO - CA Cancer J Clin VL - 68 UR - https://doi.org/10.3322/caac.21442 DO - 10.3322/caac.21442 ID - Siegel2018 ER - TY - STD TI - National Cancer Institute (NCI). Age-adjusted SEER incidence rates. https://seer.cancer.gov/faststats/selections.php?series=age. Accessed 10 Jan 2018. UR - https://seer.cancer.gov/faststats/selections.php?series=age ID - ref3 ER - TY - JOUR AU - Schöffski, P. AU - Cornillie, J. AU - Wozniak, A. AU - Li, H. AU - Hompes, D. PY - 2014 DA - 2014// TI - Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease JO - Oncol Res Treat VL - 37 UR - https://doi.org/10.1159/000362631 DO - 10.1159/000362631 ID - Schöffski2014 ER - TY - STD TI - National Cancer Institute (NCI). Adult soft tissue sarcoma treatment (PDQ); 2017. https://www.cancer.gov/types/soft-tissue-sarcoma/patient/adult-soft-tissue-treatment-pdq. Accessed 30 March 2017. UR - https://www.cancer.gov/types/soft-tissue-sarcoma/patient/adult-soft-tissue-treatment-pdq ID - ref5 ER - TY - STD TI - American Cancer Society (ACS). Survival by Stage of Soft Tissue Sarcoma; 2016. https://www.cancer.org/cancer/soft-tissue-sarcoma/detection-diagnosis-staging/survival-rates.html. Accessed 21 Sept 2017. UR - https://www.cancer.org/cancer/soft-tissue-sarcoma/detection-diagnosis-staging/survival-rates.html ID - ref6 ER - TY - JOUR AU - Italiano, A. AU - Mathoulin-Pelissier, S. AU - Cesne, A. L. AU - Terrier, P. AU - Bonvalot, S. AU - Collin, F. PY - 2011 DA - 2011// TI - Trends in survival for patients with metastatic soft-tissue sarcoma JO - Cancer VL - 117 UR - https://doi.org/10.1002/cncr.25538 DO - 10.1002/cncr.25538 ID - Italiano2011 ER - TY - JOUR AU - Spira, A. I. AU - Ettinger, D. S. PY - 2002 DA - 2002// TI - The use of chemotherapy in soft-tissue sarcomas JO - Oncologist VL - 7 UR - https://doi.org/10.1634/theoncologist.7-4-348 DO - 10.1634/theoncologist.7-4-348 ID - Spira2002 ER - TY - JOUR AU - Karavasilis, V. AU - Seddon, B. M. AU - Ashley, S. AU - Al-Muderis, O. AU - Fisher, C. AU - Judson, I. PY - 2008 DA - 2008// TI - Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients JO - Cancer VL - 112 UR - https://doi.org/10.1002/cncr.23332 DO - 10.1002/cncr.23332 ID - Karavasilis2008 ER - TY - JOUR AU - Judson, I. AU - Verweij, J. AU - Gelderblom, H. AU - Hartmann, J. T. AU - Schöffski, P. AU - Blay, J. Y. PY - 2014 DA - 2014// TI - Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced soft-tissue sarcoma: a randomised controlled phase 3 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70063-4 DO - 10.1016/S1470-2045(14)70063-4 ID - Judson2014 ER - TY - JOUR AU - Tap, W. D. AU - Jones, R. L. AU - Tine, B. A. AU - Chmielowski, B. AU - Elias, A. D. AU - Adkins, D. PY - 2016 DA - 2016// TI - Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial JO - Lancet VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)30587-6 DO - 10.1016/S0140-6736(16)30587-6 ID - Tap2016 ER - TY - STD TI - United States Food and Drug Administration (FDA). FDA grants accelerated approval to new treatment for advanced soft tissue sarcoma [press release]; 2016. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm525878.htm. Accessed 7 July 2017. UR - https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm525878.htm ID - ref12 ER - TY - JOUR AU - Demetri, G. D. AU - Mehren, M. AU - Jones, R. L. AU - Hensley, M. L. AU - Schuetze, S. M. AU - Staddon, A. AU - Milhem, M. AU - Elias, A. AU - Ganjoo, K. AU - Tawbi, H. AU - Tine, B. A. PY - 2015 DA - 2015// TI - Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.62.4734 DO - 10.1200/JCO.2015.62.4734 ID - Demetri2015 ER - TY - JOUR AU - Graaf, W. T. AU - Blay, J. Y. AU - Chawla, S. P. AU - Kim, D. W. AU - Bui-Nguyen, B. AU - Casali, P. G. AU - Schöffski, P. AU - Aglietta, M. AU - Staddon, A. P. AU - Beppu, Y. AU - Cesne, A. PY - 2012 DA - 2012// TI - Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial JO - Lancet VL - 379 UR - https://doi.org/10.1016/S0140-6736(12)60651-5 DO - 10.1016/S0140-6736(12)60651-5 ID - Graaf2012 ER - TY - JOUR AU - Warren, J. L. AU - Klabunde, C. N. AU - Schrag, D. AU - Bach, P. B. AU - Riley, G. F. PY - 2002 DA - 2002// TI - Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population JO - Med Care VL - 40 ID - Warren2002 ER - TY - JOUR AU - Nattinger, A. B. AU - McAuliffe, T. L. AU - Schapira, M. M. PY - 1997 DA - 1997// TI - Generalizability of the Surveillance, Epidemiology, and End Results registry population: factors relevant to epidemiologic and health care research JO - J Clin Epidemiol VL - 50 UR - https://doi.org/10.1016/S0895-4356(97)00099-1 DO - 10.1016/S0895-4356(97)00099-1 ID - Nattinger1997 ER - TY - STD TI - World Health Organization (WHO). International classification of diseases for oncology (ICD-O), 3rd edition, 1st revision; 2013. http://apps.who.int/iris/bitstream/10665/96612/1/9789241548496_eng.pdf. Accessed June 2017. UR - http://apps.who.int/iris/bitstream/10665/96612/1/9789241548496_eng.pdf ID - ref17 ER - TY - BOOK PY - 2013 DA - 2013// TI - WHO classification of tumours of soft tissue and bone PB - World Health Organization CY - Lyon ID - ref18 ER - TY - STD TI - American Joint Committee on Cancer. Cancer staging manual. 6th edition; 2002. https://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx. Accessed 26 June 2017. UR - https://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx ID - ref19 ER - TY - STD TI - National Cancer Institute (NCI). SEER summary staging manual—2000: codes and coding instructions; 2000. https://seer.cancer.gov/tools/ssm/. Accessed 9 June 2017. UR - https://seer.cancer.gov/tools/ssm/ ID - ref20 ER - TY - JOUR AU - Charlson, M. E. AU - Pompei, P. AU - Ales, K. L. AU - MacKenzie, C. R. PY - 1987 DA - 1987// TI - A new method of classifying prognostic comorbidity in longitudinal studies: development and validation JO - J Chronic Dis VL - 40 UR - https://doi.org/10.1016/0021-9681(87)90171-8 DO - 10.1016/0021-9681(87)90171-8 ID - Charlson1987 ER - TY - JOUR AU - Charlson, M. E. AU - Charlson, R. E. AU - Peterson, J. C. AU - Marinopoulos, S. S. AU - Briggs, W. M. AU - Hollenberg, J. P. PY - 2008 DA - 2008// TI - The Charlson Comorbidity Index is adapted to predict costs of chronic disease in primary care patients JO - J Clin Epidemiol VL - 61 UR - https://doi.org/10.1016/j.jclinepi.2008.01.006 DO - 10.1016/j.jclinepi.2008.01.006 ID - Charlson2008 ER - TY - JOUR AU - Deyo, R. A. AU - Cherkin, D. C. AU - Ciol, M. A. PY - 1992 DA - 1992// TI - Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases JO - J Clin Epidemiol VL - 45 UR - https://doi.org/10.1016/0895-4356(92)90133-8 DO - 10.1016/0895-4356(92)90133-8 ID - Deyo1992 ER - TY - STD TI - National Comprehensive Cancer Network (NCCN). Soft tissue sarcoma. NCCN Clinical Practice Guidelines in Oncology; 2017 https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed June 2017. UR - https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf ID - ref24 ER - TY - JOUR AU - Wagner, M. J. AU - Amodu, L. I. AU - Duh, M. S. AU - Korves, C. AU - Solleza, F. AU - Manson, S. C. PY - 2015 DA - 2015// TI - A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments JO - BMC Cancer VL - 15 UR - https://doi.org/10.1186/s12885-015-1182-4 DO - 10.1186/s12885-015-1182-4 ID - Wagner2015 ER - TY - JOUR AU - Leahy, M. AU - Garcia Del Muro, X. AU - Reichardt, P. AU - Judson, I. AU - Staddon, A. AU - Verweij, J. PY - 2012 DA - 2012// TI - Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The Sarcoma treatment and Burden of Illness in North America and Europe (SABINE) study JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mds070 DO - 10.1093/annonc/mds070 ID - Leahy2012 ER - TY - JOUR AU - Matushansky, I. AU - Dela Cruz, F. AU - Insel, B. J. AU - Hershman, D. L. AU - Neugut, A. I. PY - 2013 DA - 2013// TI - Chemotherapy use in elderly patients with soft tissue sarcoma: a population-based study JO - Cancer Invest VL - 31 UR - https://doi.org/10.3109/07357907.2012.756112 DO - 10.3109/07357907.2012.756112 ID - Matushansky2013 ER - TY - JOUR AU - Skubitz, K. M. AU - Haddad, P. A. PY - 2005 DA - 2005// TI - Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma JO - Cancer VL - 104 UR - https://doi.org/10.1002/cncr.21140 DO - 10.1002/cncr.21140 ID - Skubitz2005 ER - TY - JOUR AU - Penel, N. AU - Bui, B. N. AU - Bay, J. O. AU - Cupissol, D. AU - Ray-Coquard, I. AU - Piperno-Neumann, S. PY - 2008 DA - 2008// TI - Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2008.17.3146 DO - 10.1200/JCO.2008.17.3146 ID - Penel2008 ER - TY - JOUR AU - Schlemmer, M. AU - Reichardt, P. AU - Verweij, J. AU - Hartmann, J. T. AU - Judson, I. AU - Thyss, A. PY - 2008 DA - 2008// TI - Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group JO - Eur J Cancer VL - 44 UR - https://doi.org/10.1016/j.ejca.2008.07.037 DO - 10.1016/j.ejca.2008.07.037 ID - Schlemmer2008 ER - TY - JOUR AU - Chatterjee, K. AU - Zhang, J. AU - Honbo, N. AU - Karliner, J. S. PY - 2010 DA - 2010// TI - Doxorubicin cardiomyopathy JO - Cardiology VL - 115 UR - https://doi.org/10.1159/000265166 DO - 10.1159/000265166 ID - Chatterjee2010 ER - TY - JOUR AU - Volkova, M. AU - Russell, R. PY - 2011 DA - 2011// TI - Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment JO - Curr Cardiol Rev VL - 7 UR - https://doi.org/10.2174/157340311799960645 DO - 10.2174/157340311799960645 ID - Volkova2011 ER - TY - JOUR AU - Hershman, D. L. AU - McBride, R. B. AU - Eisenberger, A. AU - Tsai, W. Y. AU - Grann, V. R. AU - Jacobson, J. S. PY - 2008 DA - 2008// TI - Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.14.1242 DO - 10.1200/JCO.2007.14.1242 ID - Hershman2008 ER - TY - JOUR AU - Mir, O. AU - Domont, J. AU - Cioffi, A. AU - Bonvalot, S. AU - Boulet, B. AU - Pechoux, C. AU - Terrier, P. AU - Spielmann, M. AU - Cesne, A. PY - 2011 DA - 2011// TI - Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma JO - Eur J Cancer VL - 47 UR - https://doi.org/10.1016/j.ejca.2010.11.025 DO - 10.1016/j.ejca.2010.11.025 ID - Mir2011 ER - TY - JOUR AU - Ferreira, A. L. AU - Matsubara, L. S. AU - Matsubara, B. B. PY - 2008 DA - 2008// TI - Anthracycline-induced cardiotoxicity JO - Cardiovasc Hematol Agents Med Chem (Former Curr Med ChemistryCardiovasc Hematol Agents) VL - 6 UR - https://doi.org/10.2174/187152508785909474 DO - 10.2174/187152508785909474 ID - Ferreira2008 ER - TY - JOUR AU - Davis, K. L. AU - Goyal, R. K. AU - Able, S. L. AU - Brown, J. AU - Li, L. AU - Kaye, J. A. PY - 2015 DA - 2015// TI - Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer JO - Lung Cancer VL - 87 UR - https://doi.org/10.1016/j.lungcan.2014.11.002 DO - 10.1016/j.lungcan.2014.11.002 ID - Davis2015 ER - TY - JOUR AU - Schöffski, P. AU - Chawla, S. AU - Maki, R. G. AU - Italiano, A. AU - Gelderblom, H. AU - Choy, E. PY - 2016 DA - 2016// TI - Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(15)01283-0 DO - 10.1016/S0140-6736(15)01283-0 ID - Schöffski2016 ER - TY - STD TI - National Cancer Institute (NCI). Measures that are limited or not available in the data; 2015. https://healthcaredelivery.cancer.gov/seermedicare/considerations/measures.html. Accessed 21 Sept 2017. UR - https://healthcaredelivery.cancer.gov/seermedicare/considerations/measures.html ID - ref38 ER - TY - JOUR AU - Chawla, N. AU - Yabroff, K. R. AU - Mariotto, A. AU - McNeel, T. S. AU - Schrag, D. AU - Warren, J. L. PY - 2014 DA - 2014// TI - Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage JO - Ann Epidemiol VL - 24 UR - https://doi.org/10.1016/j.annepidem.2014.06.099 DO - 10.1016/j.annepidem.2014.06.099 ID - Chawla2014 ER -